CLARIVATE PLC (CLVT) stock intrinsic value fair value estimate & owner earnings analysis

Clarivate sells subscription data and software to universities, libraries, governments and patent owners. Its main products are Web of Science, ProQuest and the Ex Libris library systems in Academia & Government, and Derwent and patent-renewal services in Intellectual Property. In July 2026 it agreed to sell its Life Sciences & Healthcare segment to Altaris for $600 million: $500 million in cash at closing, $25 million deferred and a $75 million seller note. Closing is expected by year-end, and the company says the cash will go to repaying debt. That segment's profit fell from $158 million in 2023 to $120 million in 2025, the fastest decline in the company, so the business that remains shrinks more slowly than Clarivate as a whole. About 65% of 2025 revenue came from subscriptions, 18% from recurring patent-renewal work and 17% from one-off sales and services. Subscription revenue has held roughly flat for three years ($1,618M, $1,627M, $1,606M). One-off revenue has fallen steeply, from $566M to $500M to $416M. That shrinking one-off business is most of why total revenue fell from $2,629M in 2023 to $2,455M in 2025. In the first half of 2026, organic subscription revenue grew 0.7% while one-off revenue fell 15.7%. How we measure earning power: we start with operating cash flow, strip out working-capital swings, and subtract share-based pay and the capital spending needed to keep the business running. Because Clarivate is heavily indebted, we value the business before interest and then subtract what it owes. On that basis the business produced about $638M in 2023, $587M in 2024 and $559M in 2025. We estimate roughly 12% of this came from the segment being sold, based on its share of segment profit, which leaves about $492M in 2025 for the continuing business. That business fell about 3.6% in 2025. Large amortisation charges from past acquisitions are added back as non-cash. Because acquired content and technology wear out, we assume no growth in any case to offset them. First-half 2026 cash flow looked weak at first glance (operating cash flow down 19%). The cause was timing in payables, prepaid expenses and receivables. Before those swings, first-half owner earnings actually rose from about $124M to $150M, partly because capital spending was lower. Base case, $4.50 per share: the continuing business declines about 2% in 2026. We start above the 3.6% decline of 2025 because first-half 2026 results improved. It then declines 2-2.5% a year through 2029 and 1.5% a year indefinitely after that. The decline eases because the shrinking one-off revenue becomes a smaller part of the whole, while the subscription base, which has held flat for three years, carries most of the value. We credit no growth, no margin expansion and no benefit from management's targets. The business is worth about $7.0 billion including the sale proceeds. It owes about $4.14 billion ($4.25 billion of debt less about $118 million of cash beyond operating needs), leaving about $2.9 billion for shareholders. Bear case, $1.18 per share: the continuing business declines 4% in 2026, then 6% a year through 2030, matching its worst recent year, and 4% a year after that. The $846 million of 3.875% notes due 2028 and the $921 million of 4.875% notes due 2029 are refinanced at about 8%, which adds about $130 million to what shareholders effectively owe. The business is worth about $5.0 billion against about $4.26 billion owed, so shareholders keep only about $0.76 billion. In this case, small changes in business value swing the share value sharply. Bull case, $7.01 per share: organic contract value, up 1.5% at June 30, 2026, and steady renewals offset the shrinking one-off revenue. The continuing business holds at its 2025 level through 2035 and then declines 0.5% a year. The business is worth about $8.6 billion against about $4.13 billion owed. Debt: $4.25 billion at June 30, 2026, made up of the 2028 and 2029 notes and about $2.45 billion of term loans due January 2031, priced at the SOFR benchmark rate plus 2.75-3.25%. The cheap fixed-rate notes roughly offset the higher-cost term loans, so we make no net adjustment for borrowing costs in the base case. The company bought back $75 million of the 2028 notes in the second quarter at about 97 cents on the dollar, which does not suggest lenders are worried. In every case, the business's cash flow before interest stays well above its roughly $250 million annual interest bill. What would make this wrong: a faster loss of subscribers in research databases, or a failure to refinance the 2028-2029 notes on reasonable terms, would push value toward the bear case. With about $4 billion owed, a 10% change in what the business is worth moves the share value by roughly 25%. If the Altaris sale failed to close, the segment would stay with Clarivate and keep shrinking, which is worth roughly $250 million less than the sale price. We could not see exactly how capital spending and overhead are split between the segment being sold and the rest, so we split cash flow by segment profit. Margin-of-safety price: given the debt and the shrinking business, the margin-of-safety price is around $2.00 per share, and it applies once the segment sale has closed and the proceeds have gone to repaying debt.